-
Suzlon Energy
74.30 86.04(%) -
Reliance Power
60.50 60.50(%) -
Swiggy
338.00 617.00(%) -
Mazagon Dock
3,450.00 1,200.00(%) -
Eternal Ltd
243.00 304.50(%) -
MMTC
88.20 131.88(%) -
Garden Reach Sh.
2,926.85 1,148.10(%) -
Waaree Energies
2,956.60 1,808.65(%) -
Indian Energy Ex
203.20 244.35(%) -
Bharat Dynamics
2,096.00 2,096.00(%) -
Engineers India
239.00 304.00(%) -
NBCC
126.41 139.83(%) -
IFCI
66.71 35.67(%) -
Muthoot Finance
2,241.75 2,444.65(%) -
HDFC Bank
1,948.60 1,977.95(%) -
LMW
16,640.85 13,456.85(%) -
Hind.Aeronautics
4,962.00 3,045.95(%) -
Pidilite Inds.
3,127.25 3,414.40(%) -
Infosys
1,555.10 1,307.10(%) -
Ola Electric
48.07 45.55(%)
- Overview
- Key Ratios
- Financials
- Shareholding
- Company Info
- Peer Comparison
- Overview
- Key Ratios
- Financials
- Shareholding
- Company Info
- Peer Comparison
Glenmark Pharmaceuticals Ltd Pharmaceuticals - Indian - Bulk Drugs & Formln
- Indian Private
- BSE Code : 20600.0
- ISIN : INE935A01035
-
Today’s Low
1,408.10 -
Today’s High
1,466.00

-
Open
1,415.00 -
Perv Close
1,406.40 -
52W Low
1,037.15 -
52W High
1,830.95
Key Indicators
-
P/E(TTM)
23.58
-
Mar.Cap (₹Cr.)
41,119.48
-
Div & Yield %
0.17
-
Book Value(₹)
868.32
-
Debt-Equity Ratio
3.60
-
AGM Date
30-May-2025
-
EPS
61.81
-
P/E Ratio
23.58
Financials Ratios
-
Debt-Equity Ratio
0.34
-
Mar.Cap (₹Cr.)
41,119.48
-
RONW (%)
-50.87
-
ROCE (%)
12.05
Score Board
-
Equity (₹ in Cr.)
28.22
-
BV (₹)
868.30
-
Sales( ₹ in Cr.)
9,010.54
-
NP (in Cr.)
1,744.30
-
NP Var(%)
22.0
-
Div%
250.0
-
CPS (₹)
69.60
-
EPS (₹)
61.80
-
Traded Value (₹ in Lakhs)
41,137.82
-
52 Week High
1,830.95
-
52 Week Low
1,037.15
-
Price BSE
1458.0
-
Price NSE
1,457.00
-
Market Capital( in Cr.)
41,137.82
-
P/C Ratio
21.00
-
P/E Ratio
23.60
-
Price Vs.BV
61.80
-
24-May-2025( 11:52)
Corporate News - Board... - Glenmark Pharmaceuticals annou...
-
24-May-2025( 07:44)
Results - Announcements - Glenm... - Net profit of Glenmark Pharmac...
-
22-May-2025( 04:03)
Corporate News - Glenm... - The Board of Glenmark Pharmace...
-
13-May-2025( 03:58)
Corporate News - Glenm... - Glenmark Pharmaceuticals will...
Navigate The Market With Confidence
Your all-in-one destination for expert investment guidance and streamlined portfolio management solutions
Financials
All Values are in (₹Cr)Particulars(INCOME) | 2024 Mar | 2023 Mar | 2022 Mar | 2021 Mar | 2020 Mar | 2019 Mar |
---|---|---|---|---|---|---|
INCOME : | ||||||
Sales Turnover | 7,891.12 | 8,220.66 | 8,141.58 | 7,567.93 | 6,712.63 | 6,304.87 |
Excise Duty | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Sales | 7,891.12 | 8,220.66 | 8,141.58 | 7,567.93 | 6,712.63 | 6,304.87 |
Other Income | 6,238.36 | 985.94 | 1,044.96 | 470.13 | 625.34 | 954.61 |
Stock Adjustments | 103.07 | 31.37 | 16.13 | -5.24 | -48.77 | -471.81 |
Total Income | 14,232.55 | 9,237.97 | 9,202.67 | 8,032.82 | 7,289.20 | 6,787.67 |
EXPENDITURE : | ||||||
Raw Materials | 3,313.19 | 3,427.07 | 3,474.66 | 2,944.53 | 2,617.22 | 1,887.15 |
Power and Fuel Cost | 104.92 | 95.09 | 91.34 | 80.49 | 90.76 | 82.99 |
Employee Cost | 1,434.78 | 1,346.51 | 1,193.20 | 1,107.40 | 1,072.33 | 969.98 |
Other Manufacturing Expenses | 375.32 | 304.66 | 297.44 | 267.26 | 230.03 | 218.75 |
Selling and Administration Expenses | 1,199.17 | 1,246.10 | 1,062.89 | 914.37 | 977.77 | 992.83 |
Miscellaneous Expenses | 325.15 | 855.71 | 349.97 | 358.30 | 371.53 | 353.89 |
Employee Benefit Expenses | 1,434.78 | 1,346.51 | 1,193.20 | 1,107.40 | 1,072.33 | 969.98 |
Less: Preoperative Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Total Expenses | 6,752.52 | 7,275.13 | 6,469.50 | 5,672.35 | 5,359.63 | 4,505.58 |
Operating Profit | 7,480.02 | 1,962.84 | 2,733.18 | 2,360.47 | 1,929.57 | 2,282.08 |
Interest | 277.11 | 206.82 | 236.04 | 265.90 | 256.39 | 223.81 |
Gross Profit | 7,202.91 | 1,756.02 | 2,497.14 | 2,094.57 | 1,673.18 | 2,058.27 |
Depreciation | 202.16 | 184.15 | 159.70 | 150.82 | 138.54 | 106.28 |
Profit Before Tax | 7,000.75 | 1,571.87 | 2,337.44 | 1,943.75 | 1,534.64 | 1,951.99 |
Current Tax | 1,049.99 | 386.93 | 411.08 | 343.62 | 269.24 | 383.50 |
Fringe Benefit tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Deferred Tax | 783.46 | -23.83 | -71.42 | -49.31 | -89.14 | -53.61 |
Reported Net Profit | 5,167.29 | 1,208.77 | 1,997.79 | 1,649.45 | 1,354.55 | 1,622.11 |
Extraordinary Items | 3,742.26 | -369.56 | 354.02 | 59.87 | 14.43 | 277.16 |
Adjusted Net Profit | 1,425.03 | 1,578.33 | 1,643.77 | 1,589.58 | 1,340.12 | 1,344.95 |
Adjustment below Net Profit | -4.76 | 0.63 | 1.61 | 2.48 | -5.42 | -3.54 |
P & L Balance brought forward | 16,002.82 | 14,863.96 | 12,921.86 | 11,340.47 | 10,059.38 | 8,508.84 |
Statutory Appropriations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Appropriations | 77.22 | 70.54 | 57.30 | 70.54 | 68.03 | 68.03 |
P & L Balance carried down | 21,088.13 | 16,002.82 | 14,863.96 | 12,921.86 | 11,340.47 | 10,059.38 |
Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Preference Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Equity Dividend (%) | 250.00 | 250.00 | 250.00 | 250.00 | 250.00 | 200.00 |
Dividend Per Share(Rs) | 2.50 | 2.50 | 2.50 | 2.50 | 2.50 | 2.00 |
Earnings Per Share-Unit Curr | 183.11 | 42.84 | 70.80 | 58.46 | 48.00 | 57.49 |
Earnings Per Share(Adj)-Unit Curr | 183.11 | 42.84 | 70.80 | 58.46 | 48.00 | 57.49 |
Book Value | 814.01 | 633.57 | 593.21 | 524.84 | 468.73 | 423.22 |
Book Value(Adj)-Unit Curr | 814.01 | 633.57 | 593.21 | 524.84 | 468.73 | 423.22 |